What is Maat?
Founded in 2014 and headquartered in Lyon, France, MaaT Pharma is at the forefront of developing innovative microbiome-based therapies. The company's core focus lies in leveraging biotherapeutics to restore the gut microbiome, aiming to provide novel treatment options for patients battling serious conditions. This strategic financing round is expected to bolster their clinical development pipeline and expand their therapeutic reach in the oncology sector.
How much funding has Maat raised?
Maat has raised a total of $100.7M across 6 funding rounds:
Unspecified
$1.3M
Unspecified
$1.1M
Series A
$11.2M
Series B
$29.5M
Share Placement
$14M
Debt
$43.7M
Unspecified (2015): $1.3M with participation from Seventure Partners
Unspecified (2015): $1.1M led by Seventure Partners
Series A (2016): $11.2M supported by Seventure Partners
Series B (2020): $29.5M featuring Seventure Partners, SymBiosis, Crédit Mutuel Innovation, Biocodex, and Bpifrance
Share Placement (2025): $14M backed by Biocodex, Bpifrance Investissement, and RiPSIM Technologies
Debt (2025): $43.7M with participation from European Investment Bank
Key Investors in Maat
Seventure Partners
Seventure Partners is a venture capital firm that actively supports innovative companies in the digital technology and life sciences sectors. They focus on health, nutrition, and biotechnology, providing crucial backing for early-stage and growth-stage companies.
European Investment Bank
The European Investment Bank (EIB) is the European Union's long-term lending institution, dedicated to financing projects that support EU policy objectives, including advancements in healthcare and biotechnology.
Biocodex
Biocodex is a multinational pharmaceutical company with a strong focus on microbiota and neurology, developing innovative healthcare solutions and investing in companies that align with their therapeutic areas.
What's next for Maat?
With a substantial enterprise-level funding injection and a recent strategic investment, MaaT Pharma is poised for accelerated growth and advancement of its clinical programs. The company's trajectory suggests a strong emphasis on scaling operations, advancing its lead candidates through late-stage clinical trials, and potentially forging new partnerships to broaden its therapeutic impact. This capital infusion is critical for navigating the complex regulatory pathways and commercialization efforts inherent in the biopharmaceutical industry, positioning MaaT Pharma for a significant role in the future of microbiome-based medicine.
See full Maat company page
